Urispas: Effective Relief for Bladder Spasms and Urinary Urgency
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.61 | $48.22 (0%) | 🛒 Add to cart |
| 60 | $1.31 | $96.43 $78.35 (19%) | 🛒 Add to cart |
| 90 | $1.22 | $144.65 $109.49 (24%) | 🛒 Add to cart |
| 120 | $1.16 | $192.87 $139.63 (28%) | 🛒 Add to cart |
| 180 | $1.12 | $289.30 $201.91 (30%) | 🛒 Add to cart |
| 270 | $1.09 | $433.96 $295.33 (32%) | 🛒 Add to cart |
| 360 | $1.07
Best per pill | $578.61 $386.74 (33%) | 🛒 Add to cart |
Synonyms | |||
Urispas (flavoxate hydrochloride) is an antispasmodic medication specifically formulated to target and relieve symptoms associated with urinary tract conditions. It works by relaxing the smooth muscles of the urinary bladder, thereby reducing spasms, urgency, and frequency of urination. This medication is commonly prescribed for patients experiencing discomfort from cystitis, prostatitis, urethritis, and other related urological disorders. Clinical evidence supports its efficacy in improving quality of life by alleviating painful and disruptive urinary symptoms.
Features
- Active ingredient: Flavoxate hydrochloride 100 mg per tablet
- Anticholinergic and direct smooth muscle relaxant properties
- Rapid onset of action, typically within 60 minutes of administration
- Convenient oral tablet formulation
- Prescription-only medication ensuring supervised use
Benefits
- Reduces urinary urgency and frequency, allowing for better daily planning and uninterrupted sleep
- Alleviates bladder pain and discomfort associated with muscle spasms
- Minimizes involuntary bladder contractions, providing sustained symptom relief
- Supports improved bladder control and reduces incontinence episodes
- Enhances overall quality of life by managing chronic urinary symptoms effectively
- Non-narcotic formulation with a favorable safety profile for long-term use
Common use
Urispas is primarily indicated for the symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency, and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis, or urethrotrigonitis. It is often prescribed alongside antibiotics when infection is present or as monotherapy for non-infectious bladder spasms. Healthcare providers may also recommend it for patients undergoing urological procedures to manage postoperative bladder discomfort.
Dosage and direction
The usual adult dosage is one or two 100 mg tablets three or four times daily. Dosage may be adjusted based on symptom severity and patient response. Tablets should be swallowed whole with a full glass of water, with or without food. It is recommended to take doses at evenly spaced intervals throughout the day to maintain consistent therapeutic levels. Do not crush or chew tablets. Treatment duration varies depending on the condition being treated; follow your healthcare provider’s instructions precisely.
Precautions
Patients with glaucoma, particularly narrow-angle glaucoma, should use Urispas with extreme caution due to its anticholinergic effects. Those with gastrointestinal obstruction, urinary retention, or severe ulcerative colitis require careful monitoring while taking this medication. Elderly patients may be more sensitive to anticholinergic effects and should be monitored for confusion, dizziness, or drowsiness. Use during pregnancy only if clearly needed and after thorough risk-benefit assessment. Nursing mothers should consult their physician before use as flavoxate may be excreted in breast milk.
Contraindications
Urispas is contraindicated in patients with known hypersensitivity to flavoxate hydrochloride or any component of the formulation. It should not be used in patients with pyloric or duodenal obstruction, obstructive intestinal lesions, ileus, megalolon, or severe ulcerative colitis. Contraindicated in patients with uncompensated cardiac disease or myasthenia gravis. Should not be administered to patients with urinary or gastric retention unless adequate outflow has been established.
Possible side effects
Common side effects may include dizziness, drowsiness, blurred vision, dry mouth, nausea, and nervousness. Less frequently reported effects include headache, insomnia, confusion (particularly in elderly patients), tachycardia, palpitations, increased intraocular pressure, and skin rash. Gastrointestinal effects such as vomiting, abdominal pain, or constipation may occur. Most side effects are dose-dependent and often diminish with continued therapy. Report any persistent or severe side effects to your healthcare provider promptly.
Drug interaction
Urispas may potentiate the effects of other anticholinergic drugs, including tricyclic antidepressants, antihistamines, phenothiazines, and anti-Parkinsonism agents. Concurrent use with monoamine oxidase inhibitors (MAOIs) may intensify anticholinergic effects. May reduce gastrointestinal motility and affect absorption of other medications. Caution is advised when combining with sedatives or CNS depressants as additive effects may occur. Inform your physician about all prescription medications, over-the-counter drugs, and herbal supplements you are taking.
Missed dose
If you miss a dose of Urispas, take it as soon as you remember unless it is almost time for your next scheduled dose. In that case, skip the missed dose and resume your regular dosing schedule. Do not double the dose to make up for a missed one. Maintaining consistent blood levels is important for optimal therapeutic effect, so try to establish a routine for medication administration.
Overdose
Symptoms of overdose may include severe anticholinergic effects such as dilated pupils, blurred vision, flushed skin, dry mouth, difficulty swallowing, tachycardia, hyperthermia, restlessness, confusion, hallucinations, or seizures. In severe cases, cardiovascular collapse or respiratory depression may occur. Treatment is primarily supportive and symptomatic. Gastric lavage may be considered if ingestion was recent. Activated charcoal may be administered. Physostigmine may be used in severe cases under careful medical supervision. Seek immediate medical attention if overdose is suspected.
Storage
Store Urispas tablets at room temperature (15-30°C or 59-86°F) in their original container, tightly closed and protected from light and moisture. Keep out of reach of children and pets. Do not store in bathroom areas where moisture levels may vary. Properly discard any expired or unused medication according to local guidelines or through medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual responses to medication may vary. Always consult with a qualified healthcare professional before starting, stopping, or changing any medication regimen. The prescribing physician should be aware of the patient’s complete medical history and current medications. Proper diagnosis and monitoring are essential for safe and effective treatment.
Reviews
Clinical studies have demonstrated Urispas to be effective in reducing urinary symptoms in 70-80% of patients with various urological conditions. Many patients report significant improvement in urgency and frequency within the first week of treatment. Some users note mild drowsiness initially that typically subsides with continued use. Healthcare providers appreciate its targeted action on bladder musculature with fewer systemic effects compared to some alternatives. Long-term users report maintained efficacy with appropriate dosage adjustments when necessary.